Affordable Access

deepdyve-link
Publisher Website

Aldehyde dehydrogenase-2 is a host factor required for effective bone marrow mesenchymal stem cell therapy.

Authors
  • Zhu, Hongming1
  • Sun, Aijun
  • Zhu, Hong
  • Li, Zheng
  • Huang, Zheyong
  • Zhang, Shuning
  • Ma, Xin
  • Zou, Yunzeng
  • Hu, Kai
  • Ge, Junbo
  • 1 From the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases (Hongming Zhu, A.S., Hong Zhu, Z.H., S.Z., X.M., Y.Z., K.H., J.G.), Biomedical Research Center (Z.L.), Zhongshan Hospital, and Institute of Biomedical Science (H.Z.), Fudan University, Shanghai, China. , (China)
Type
Published Article
Journal
Arteriosclerosis Thrombosis and Vascular Biology
Publisher
Ovid Technologies Wolters Kluwer -American Heart Association
Publication Date
Apr 01, 2014
Volume
34
Issue
4
Pages
894–901
Identifiers
DOI: 10.1161/ATVBAHA.114.303241
PMID: 24558108
Source
Medline
Keywords
License
Unknown

Abstract

Our study establishes ALDH2 as a key mediator of host stem cell niche for optimal MSC therapy and suggests that ALDH2 deficiency present in the general population is a limiting host factor to be considered for MSC therapy.

Report this publication

Statistics

Seen <100 times